Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000491

Drug Information
NameQuinine    
SynonymsInChI=1/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H; Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-; 804-63-7; 909767-48-2; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; NSC131458; 864908-93-0; NCGC00159499-02; IBS-L0034250; Quniacridine; .alpha.-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; 6-Methoxycinchonine; 767303-40-2; Chinine; LS-141252; 898813-59-7; 898814-28-3; Cin-Quin; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; 6'-Methoxycinchonan-9-ol; nchembio.87-comp19; CHEBI:15854; HMS1791J11; NSC5362; (8S,9R)-Quinine; Chinin [German]; I14-3397; AC1MI1Q5; (3|A,8|A,9r)-6'-methoxycinchonan-9-ol; Kinder Quinina (TN); MolPort-002-507-196; QUININE MONO HCL; NSC 5362; Quinine sulphate; chininum; CID637552; NCGC00142453-01; NCGC00162322-02; 888714-03-2; Conchinin; Quinine Dab; Quinimax; 6183-68-2; CCRIS 5755; NCGC00166281-01; WLN: T66 BNJ HO1 EYQ-DT66 A B CNTJ A1U1; 12239-42-8; Kinder Quinina; Quinidex; (8S,9R)-6'-Methoxycinchonan-9-ol; 840482-04-4; (-)-Quinine; CID1065; 900789-95-9; 909263-47-4; nchembio.215-comp5; C20H24N2O2; SMR000718748; NSC192949; Quinsan (*2:1 Sulfate salt*), dihydrate; 56-54-2; MolPort-000-146-082; AC1Q4EZ5; LS-194958; Quinoline alkaloid; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; NCGC00162322-01; CID441073; 128544-03-6; Quine (*2:1 Sulfate salt*, dihydrate); Cinchonan-9-ol, 6'-methoxy-, (9S)-; EINECS 205-003-2; quinine sulfate; nchem.180-comp1a; SB01652; (R)-(-)-quinine; nchem.1039-compI; NCGC00015871-03; DB00468; 22620_FLUKA; MolPort-001-766-747; Quinine, polymers; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; NSC667852; NCI60_004320; LT00645788; AC1MHWS7; ST056282; L001278; (+)-Quinidine; AC1L9AHT; MLS001304041; Quinine [BAN]; quinidine; HMS1607A11; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; LS-4562; 890027-24-4; AC1L1R7Y; Quinine, tannate; Quinamm (*2:1 Sulfate salt*), dihydrate; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; 899813-83-3; Coco-Quinine; AR-1H2065; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; Quinine anhydrous; Q0028; 130-89-2; 145904_ALDRICH; 2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-; nchembio.368-comp9; Quinine; 2-Quinuclidinemethanol, .alpha.-(6-methoxy-4-quinolyl)-5-vinyl-; BB_NC-0697; Cinchonan-9-ol, 6'-methoxy-; 6'-Methoxycinchonidine; 549-56-4; D08460; CID3036746; NCGC00159499-03; (R)-(-)-Quinine, 6-methoxycinchonidine; 21480-31-9; KST-1A1085; NSC 192949; Chinin; 1407-83-6; AR-1A4833; 72646-90-3; 910878-25-0; CHEMBL170; HSDB 2501; 909882-78-6; Quinora; beta-Quinine; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; Quinine bisulfate; 906550-97-8; 6119-70-6; 875538-34-4; 911445-75-5; 130-95-0; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; CID8549; AC1L1ANE; quinina; Biquinate (*Bisulfate heptathydrate*); 900786-66-5; AC1LCUGN; 6'-Methoxycinchonine; 894767-09-0; C06526; 910880-97-6; CHEBI:111177; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; Quinine, Anhydrous; AC1Q58AF; Dentojel (*Bisulfate heptathydrate*); Conquinine; 22620_SIGMA; MolPort-003-901-021; Aflukin; HMS2089E05; 55980-20-6; Lopac0_001029; Quinine (BAN); 6912-57-8; Cinchonan-9-ol, 6'-methoxy-, (8-alpha,9R)-; I14-3348; 918778-04-8; CHEMBL97; Quindan; NCGC00163142-03; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; UNII-A7V27PHC7A; EINECS 215-805-4; 857212-53-4; Quinineanhydrous; CID3034034    
Trade NameLegatrin    
CompanyPfizer Pharmaceuticals    
IndicationMalariaApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntimalarials    
CAS NumberCAS 130-95-0
FormularC20H24N2O2    
PubChem Compound IDCID 8549.    
PubChem Substance IDSID 8757.    
ChEBI15854;    
SuperDrug ATC IDC01BA01;    
SuperDrug CAS ID000056542;    
TargetIntermediate conductance calcium-activated potassium channel protein 4Blocker[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021799 To Reference
Ref 2Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8. Epub 2006 Jun 1. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543